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Targeting the STAT5 pathway in Ph+ acute lymphoblastic 
leukemia
Valentina Minieri, Marco De Dominici, Marja T. Nevalainen and Bruno Calabretta
Ph+ ALL accounts for up to 25-30% of adult 
ALL, and its clinical outcome remains unfavorable in 
approximately 50% of the patients despite the introduction 
of more effective induction and consolidation therapies 
consisting of BCR-ABL1 tyrosine kinase inhibitors 
(TKI) in combination with cytotoxic agents followed 
by hematopoietic stem cell transplantation (HSCT) [1]. 
Resistance to TKIs develops in most patients through the 
outgrowth of leukemic subclones carrying mutations in 
the BCR-ABL1 kinase domain that impede the binding 
of these drugs to the ATP-binding pocket. Less frequently, 
resistance develops in the absence of tyrosine kinase 
domain mutations, implying that BCR-ABL1-independent 
mechanisms may be crucial in such instances. In particular, 
such mechanisms may involve microenvironment-
regulated pathways that bypass BCR-ABL1-dependent 
cell-autonomous growth-promoting signals. Hence, 
a more effective therapy of Ph+ ALL, especially at the 
TKI-resistant stage, is likely to depend on targeting 
growth-promoting pathways that are simultaneously 
activated via cell-autonomous and microenvironment-
dependent mechanisms. One such pathway is STAT5 that 
is constitutively active in Ph+ ALL cells through BCR-
ABL1 and can be activated by JAK2 via stroma-derived 
cytokines (Figure 1). 
The role of STAT5 for maintenance of oncogenic 
ABL1-driven ALL has been previously investigated 
in STAT5-deficient transgenic mice [2, 3]. Although 
disease outcomes were, in part, influenced by the genetic 
background of recipient mice, such studies supported 
the relevance of STAT5 in growth and progression of 
BCR-ABL1-driven leukemias. However, there is little 
information on the requirement of STAT5 and STAT5-
regulated pathways in patient-derived Ph+ ALL and 
whether such pathways can be targeted therapeutically in 
xenograft models of human Ph+ ALL. 
In a recently published study [4], we used genetic 
and pharmacological approaches to investigate the 
consequences of inhibiting the activity of STAT5 and 
STAT5-regulated pathways for ex vivo growth and 
leukemogenesis of Ph+ cell lines and patient-derived 
newly diagnosed and relapsed/TKI-resistant Ph+ ALL.
Compared to controls, Ph+ ALL cell lines and 
primary Ph+ ALL cells lentivirally transduced with a 
STAT5 shRNA or treated with IST5-002, a recently 
developed small molecule STAT5 inhibitor [5], exhibited 
reduced cell growth and enhanced apoptosis. IST5-002 
has been shown to inhibit phosphorylation, dimerization, 
nuclear translocation, DNA binding and transcriptional 
activity of STAT5 [5]. In addition, doxycycline-induced 
activation of a STAT5 shRNA or treatment with IST5-002 
led to a markedly increased survival of immunodeficient 
mice injected with Ph+ ALL cell lines or Ph+ ALL cells 
derived from a patient with TKI-resistant disease. 
Induction of apoptosis in STAT5-silenced Ph+ 
ALL cells was associated with downregulation of BCL-
2 and MCL-1 and upregulation of BIM expression. In 
STAT5-silenced Ph+ BV173 cells, apoptosis was rescued 
by BIM silencing or by ectopic BCL-2 expression while 
restoration of MCL-1 levels had no effects on cell viability. 
However, it is possible that other Ph+ ALL cell lines and, 
more importantly, primary Ph+ ALL cells rely on MCL-1 
expression for their survival.
Inhibition of cell growth induced by STAT5 
silencing in Ph+ ALL cells was also associated with 
decreased expression of c-MYC and the PIM-1 kinase. 
Surprisingly, restoring PIM-1 expression in STAT5-
silenced Ph+ ALL cells did not rescue growth inhibition 
induced by STAT5 silencing. This is most likely due 
to the inability of PIM-1 to suppress the apoptosis of 
STAT5-silenced Ph+ ALL cells which is associated with 
upregulation of BIM levels. In contrast, pharmacological 
              Editorial
Figure 1: STAT5 activation in Ph+ ALL and pathway 
inhibitors. STAT5 is phosphorylated and activated in Ph+ ALL 
cells by means of JAK-dependent microenvironmental cues, 
including activation of the IL-7 receptor, and, most importantly, 
by BCR-ABL1, directly or via JAK2. STAT5 activity can be 
prevented by inhibiting its phosphorylation by BCR-ABL1, by 
using direct STAT5 inhibitors such as IST5-002 or by acting on 
its transcriptional targets such as PIM-1 and BCL-2 proteins.
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inhibition of PIM kinase by treatment with the PIM1/2 
kinase inhibitor, AZD1208, suppressed proliferation and 
colony formation of Ph+ ALL cells, including primary 
leukemia cells from newly diagnosed and relapsed 
patients. AZD1208 suppression of cell viability was 
associated with decreased phosphorylation of known PIM 
kinase targets such as the eukaryotic elongation factor 4E-
BP1, pro-apoptotic protein BAD, and MYC itself.
Based on these findings, we reasoned that 
simultaneous targeting of STAT5-induced anti-apoptotic 
and growth-promoting pathways may mimic the effects of 
STAT5 silencing inducing a more effective suppression of 
Ph+ ALL cell growth ex vivo and in mice.
Indeed, combined treatment of Ph+ ALL cells with 
the pan-BCL-2 antagonist Sabutoclax and the PIM kinase 
inhibitor AZD1208 suppressed colony formation and 
leukemogenesis in immunodeficient mice more effectively 
than either treatment alone. 
In summary, this work supports the essential role of 
STAT5 and STAT5-regulated pathways for maintenance 
of Ph+ ALL cell growth. Most of the studies were based 
on genetic silencing of STAT5 or modulation of STAT5-
regulated pathways in leukemic cells to suppress BCR-
ABL1-driven STAT5 activity. However, pharmacological 
inhibition of STAT5 and STAT5-regulated pathways 
was also achieved ex vivo in cytokine-supplemented 
cell cultures that may also promote STAT5 activation 
independently of BCR-ABL1. Given that inhibition of 
STAT5 activity and suppression of Ph+ ALL cell growth 
were also achieved in these conditions, STAT5 inhibitors 
may also disrupt microenvironment-dependent activation 
of STAT5 in leukemic cells, possibly bypassing cell-
autonomous mechanisms of resistance to TKIs.
Our study supports the importance of further 
development of STAT5 inhibitors for a therapy for BCR-
ABL1-driven malignancies, especially at the stage of 
TKI-resistant disease. However, until effective STAT5 
inhibitors are brought to the clinic, the simultaneous 
targeting of STAT5-dependent growth-promoting and 
anti-apoptotic pathway may represent an alternative, while 
other strategies may be also be investigated in parallel.
For example, increased expression of BIM was 
observed in STAT5-silenced Ph+ ALL cells and BIM 
silencing alone was sufficient to suppress the apoptosis of 
these cells. BIM-mimetics [6] or drugs that enhance BIM 
activity by blocking its binding to MCL-1 antagonists [7] 
may also provide an alternative approach for the treatment 
of TKI-resistant Ph+ ALL. 
STAT5 is frequently activated in a cytokine-
independent manner in Ph-like ALL due to mutations/
translocations of genes such as JAK2, CRLF2, ABL1, 
CSF1R, and PDGFRB [8, 9]. Therefore targeting STAT5 
or its downstream effectors may be beneficial for this 
subset of patients as well.
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